
    
      This is a phase 3b, controlled, open-label, multi-center study to evaluate safety and
      immunogenicity of Menveo after a single vaccination in healthy individuals who were
      vaccinated with Menveo or Menactra 4 to 6 years before and in vaccine-naive individuals.
      Vaccine-naive subjects: subjects who have not received any meningococcal vaccine prior to
      participation to this clinical trial.

      Subjects will be randomised into one of the two different blood draw schedules according to a
      1:1 ratio.

        -  Blood draws at Day 1, Day 4 and Day 29

        -  Blood draws at Day 1, Day 6 and Day 29
    
  